# Attention-Deficit/Hyperactivity Disorder

Diagnose ADHD through DSM-5 criteria, cross-setting impairment, collateral history, and active exclusion of competing conditions. Match treatment intensity to age, impairment, comorbidity, cardiovascular risk, adverse effects, and patient preference; monitor functional response rather than symptom scores alone.

**Clinical question:** How should physicians confirm ADHD, identify clinically important mimics and comorbidities, and individualize treatment and monitoring?

Updated: 2026-08-24T18:37:33.257571+00:00

## What matters in practice
- Confirm ADHD only when developmentally inappropriate inattentive and/or hyperactive-impulsive symptoms persist for at least 6 months, cause impairment, began before age 12 years, occur in at least 2 settings, and are not better explained by another condition. [9][15]
- Use parent and teacher rating scales plus a clinical interview to document symptoms and impairment; scales support screening and longitudinal measurement but do not replace diagnostic assessment. [1][2][15]
- For patients younger than 17 years, DSM-5 requires at least 6 symptoms in an inattentive and/or hyperactive-impulsive domain; adults require 5 symptoms. [1][23]
- Stimulants, including methylphenidate and amphetamine products, provide the largest short-term symptom effects and improve symptoms in approximately 70% of children; atomoxetine, guanfacine, and clonidine are alternatives when stimulants are ineffective, poorly tolerated, or clinically unsuitable. [3][4]
- Before and during ADHD pharmacotherapy, assess resting blood pressure and heart rate and revisit cardiovascular history because ADHD medications modestly increase both measures and rare serious cardiovascular events have been reported. [5]
- Assess psychiatric comorbidity, substance use, sleep, educational or occupational dysfunction, and safety outcomes because these factors can mimic ADHD, amplify impairment, change medication selection, and require parallel treatment. [1][7][10]

## Confirm a developmental, cross-situational disorder before prescribing

Diagnosis is clinical and requires both symptom counts and impairment.

Apply DSM-5 criteria rather than diagnosing from a single office history or rating scale. Establish a persistent pattern of inattention and/or hyperactivity-impulsivity that is developmentally inappropriate, lasts at least 6 months, interferes with functioning or development, began before age 12 years, is present in at least 2 settings, and is not better explained by another disorder. [9][15] For children younger than 17 years, document at least 6 symptoms in the relevant domain; for adults, document at least 5. [1][23]

Obtain collateral evidence before assigning a diagnosis. In children, obtain parent and teacher reports addressing symptom frequency, impairment, academic performance, environmental context, and behavior across home and school. [1][15] In adults, obtain a current functional history plus evidence of childhood-onset symptoms when feasible; the Adult ADHD Self-Report Scale is useful for screening, but a positive screen requires diagnostic interview and assessment of impairment. [23]

Classify the current presentation as predominantly inattentive, predominantly hyperactive-impulsive, or combined only after separately counting symptoms in both domains. [9] Reassess the presentation when school, work, or home demands change because symptom expression varies by developmental stage and social or academic setting. [2]
- Document impairment, not merely symptom endorsement: grades or school discipline, workplace performance, driving or accident history, relationship disruption, and inability to sustain daily responsibilities are clinically consequential outcomes. [2][7]
- Use rating scales to structure collateral symptom and impairment assessment and to follow change after intervention; do not treat a scale score as an objective diagnostic test. [1][2]
- If history shows symptoms only after a discrete mood episode, substance exposure, sleep disruption, or major environmental change, evaluate that condition before attributing the presentation to ADHD. The diagnosis requires that another condition not better explain symptoms. [9][15]

*DSM-5 diagnostic checkpoints for ADHD. [1][9][15][23]*

| Checkpoint | Required finding | Clinical action if absent |
| --- | --- | --- |
| Symptom burden | Age younger than 17 years: at least 6 symptoms in inattentive and/or hyperactive-impulsive domain; age 17 years or older: at least 5 symptoms. [1][23] | Do not diagnose ADHD solely from nonspecific executive-function complaints; identify alternative causes and reassess longitudinally. [9][15] |
| Duration | Symptoms persist for at least 6 months. [1][15] | Investigate recent-onset sleep, mood, substance, medical, or situational contributors. [9][15] |
| Developmental onset | Several symptoms present before age 12 years. [9][15] | For adults without corroborated childhood symptoms, obtain collateral history when possible and evaluate competing psychiatric or medical explanations. [23] |
| Cross-setting pattern | Symptoms occur in at least 2 settings. [9][15] | If restricted to one environment, investigate setting-specific learning, occupational, family, or environmental factors. [1][9] |
| Impairment and exclusion | Symptoms impair functioning and are not better explained by another condition. [9][15] | Address the competing disorder or contextual driver and reassess residual ADHD symptoms. [9][15] |

## Separate ADHD from common mimics and identify comorbidity that changes management

The diagnostic interview should actively test alternative explanations for inattention and impulsivity.

Perform a structured developmental, medical, psychiatric, family, prenatal/perinatal, academic, and environmental history with physical examination. [1] The practical discriminator is chronology: ADHD requires childhood-onset, persistent, cross-situational impairment, whereas symptoms emerging with depression, anxiety, trauma-related symptoms, substance use, disrupted sleep, or a new medical condition require targeted evaluation of that disorder before ADHD is considered primary. [9][15]

Screen for psychiatric comorbidity during the initial assessment and when functional decline is disproportionate to core ADHD symptoms. Adult ADHD is strongly associated with psychiatric comorbidity and functional impairment, while untreated adult ADHD is associated with substance use, accidents, suicidality, absenteeism, and impaired educational and occupational performance. [7][10] Identify urgent suicide risk, psychosis, severe mood disturbance, or intoxication/withdrawal before initiating a routine outpatient ADHD medication plan.

For children with school-specific difficulty, collect teacher reports and academic performance data before interpreting poor concentration as ADHD. [1] A cross-setting pattern supports ADHD; impairment confined to particular academic tasks or settings should prompt assessment of educational and environmental contributors rather than automatic escalation of medication. [1][9]
- Ask specifically about sleep disturbance before starting medication because sleep problems are common in ADHD and may also worsen during stimulant treatment. [18]
- Ask about reduced appetite, insomnia, mood lability, and tic history before treatment because each may complicate stimulant tolerability. [18]
- Assess substance-use history and diversion risk before prescribing a stimulant because stimulant medications have abuse liability. [4]
- Review cardiovascular history and examine resting blood pressure and heart rate before medication selection because stimulants and other ADHD medications can increase both measures. [5]

*Clinical patterns that should redirect the ADHD evaluation. [1][7][9][10][15][18]*

| Pattern | Interpretation | Next action |
| --- | --- | --- |
| Symptoms confined to one setting | Does not meet the required cross-situational pattern. [9][15] | Obtain collateral reports and investigate setting-specific academic, occupational, family, or environmental stressors. [1] |
| Recent onset after mood, anxiety, trauma, substance, sleep, or medical change | Another disorder may better explain symptoms. [9][15] | Evaluate and treat the temporally linked condition; reassess attentional symptoms after stabilization. [9][15] |
| Marked functional decline with psychiatric symptoms | Comorbidity may be driving impairment and safety risk. [7][10] | Complete psychiatric assessment, including suicide and substance-use evaluation; coordinate treatment of both conditions. [7] |
| Baseline insomnia, appetite concern, mood lability, or tic history | Higher likelihood of clinically relevant treatment-emergent adverse effects. [18] | Document baseline severity and use it when selecting and monitoring medication. [18] |
| Cardiovascular disease, arrhythmia history, or elevated resting vital signs | Medication risk-benefit assessment requires greater caution. [3][5] | Review cardiovascular history, measure heart rate and blood pressure, and individualize medication selection and monitoring. [5] |

## Select treatment by age, impairment, response, tolerability, and safety constraints

Use multimodal care, with medication decisions linked to measurable functional targets.

For patients with clinically significant ADHD, establish target outcomes before treatment: classroom behavior and academic productivity in children; work completion, driving safety, relationship functioning, and daily-task execution in adults. ADHD medications and nonpharmacologic approaches can reduce symptoms and associated impairment, but treatment response should be judged against the patient’s specific functional goals as well as symptom change. [2]

Stimulant medications, including methylphenidate and amphetamine products, are the principal pharmacologic options and have the strongest short-term efficacy. In children, stimulants improve symptoms in approximately 70% and have reported short-term effect sizes of approximately 0.8 to 1.0. [3] Select formulation and titrate according to clinical response and adverse effects; do not use a single dose-response observation or neuropsychological test as a stand-alone determinant of long-term treatment choice. [16][22]

Use atomoxetine, guanfacine, or clonidine when a stimulant is ineffective, not tolerated, clinically unsuitable, or unacceptable to the patient or family. [3][4] These nonstimulants are generally considered second-line and have lower average efficacy than stimulants, but they provide a nonstimulant pathway when abuse liability, cardiovascular concerns, or stimulant adverse effects alter the balance of benefit and harm. [3][4][5]

Offer behavioral and psychosocial interventions as part of a treatment plan, particularly when impairment involves routines, parenting, school structure, emotional regulation, or adherence. Behavioral therapy, cognitive and parent training, dietary changes, and neurofeedback have more limited evidence for improving core symptoms than medication, while CBT-based interventions may improve symptom management and emotional regulation, often as adjuncts to medication. [3][8] Do not present nonpharmacologic treatment as a substitute for reassessing persistent, functionally impairing symptoms.
- Prefer a stimulant trial when rapid, substantial symptom reduction is needed and there is no patient-specific contraindication or unacceptable risk. [3][5]
- Prefer a nonstimulant pathway when stimulant adverse effects, misuse risk, or cardiovascular concerns materially outweigh expected benefit. [3][4][5]
- When adherence is poor, reassess formulation burden, adverse effects, patient preference, and comorbid conditions rather than labeling the patient treatment resistant. Adherence is particularly problematic during adolescence. [3]
- Do not recommend external trigeminal nerve stimulation, neurofeedback, dietary change, or other neuromodulatory approaches as equivalent replacements for first-line pharmacotherapy; efficacy evidence is less established or more limited. [3][8]

*Medication-class selection and key tradeoffs in ADHD. [3][4][5][18]*

| Option | When it fits | Key tradeoffs and monitoring |
| --- | --- | --- |
| Methylphenidate or amphetamine stimulant | Need for robust short-term symptom reduction; stimulants are first-line for severe ADHD. [3] | Monitor appetite, sleep, mood lability, heart rate, and blood pressure; consider misuse and abuse liability. [4][5][18] |
| Atomoxetine | Stimulant ineffective, not tolerated, or clinically unsuitable. [3][4] | Average efficacy is lower than stimulants; follow clinical response and adverse effects. [3] |
| Guanfacine or clonidine | Stimulant ineffective, not tolerated, or clinically unsuitable. [3][4] | Average efficacy is lower than stimulants; follow clinical response and adverse effects. [3] |
| CBT-based and behavioral interventions | Residual functional impairment, emotional-regulation difficulties, family or school implementation needs, or preference for adjunctive nonpharmacologic care. [3][8] | Use as an adjunct or individualized component of care; evidence for core symptom improvement is more limited than for stimulants. [3][8] |

## Monitor efficacy, adverse effects, adherence, and cardiovascular risk at every medication decision

Continue, adjust, or switch treatment using functional outcomes and measured safety parameters.

At each titration or follow-up visit, compare current symptoms and function with the baseline targets and collateral ratings. Parent and teacher scales are particularly useful for measuring change in child symptoms and impairment across settings. [1][2] If symptoms improve but academic, occupational, or family impairment persists, identify whether the residual problem is insufficient medication effect, adherence, comorbidity, sleep disturbance, or a setting-specific environmental barrier before escalating dose.

Measure resting heart rate and blood pressure before treatment and longitudinally during pharmacotherapy. ADHD medications cause modest increases in resting heart rate and blood pressure. [5] Serious outcomes including arrhythmia, nonischemic cardiomyopathy, Takotsubo cardiomyopathy, and sudden death have been reported, although reported associations do not establish causation and long-term randomized safety evidence is limited, especially in adults. [5] For patients with known cardiovascular disease or concerning symptoms, individualize treatment selection and monitoring rather than assuming stimulant risk is negligible.

Ask directly about appetite suppression, sleep disturbance, mood lability, and worsening tic symptoms, because these are clinically relevant stimulant-associated tolerability problems. [18] If adverse effects outweigh functional benefit, reduce exposure, change medication class, or prioritize nonpharmacologic supports rather than continuing an ineffective or poorly tolerated regimen. [3][18]

Reassess adherence and diversion risk, especially in adolescents and adults. Stimulant adherence declines over time, particularly in adolescence, and stimulant medications carry abuse liability. [3][4] A treatment plan that is pharmacologically effective but inconsistently taken or diverted should be considered inadequate and should trigger review of formulation, monitoring structure, patient preference, and appropriateness of a nonstimulant alternative.
- Continue a regimen only when it produces meaningful benefit in the patient’s predefined functional targets and adverse effects remain acceptable. [2][3]
- Use collateral reports to detect setting-specific nonresponse; home improvement without school improvement, or vice versa, warrants reassessment of environmental demands and comorbidity. [1][2]
- For pregnancy or postpartum treatment decisions, use individualized risk-benefit counseling. Evidence summarized in a recent review is reassuring for stimulant exposure overall, but data for second-line nonstimulants remain more limited. [20]

*Follow-up domains for ADHD pharmacotherapy. [1][3][4][5][18][20]*

| Domain | What to assess | Action triggered by an unfavorable finding |
| --- | --- | --- |
| Clinical efficacy | Core symptoms and individualized school, work, home, driving, or relationship targets. [2] | Confirm adherence and collateral observations; adjust treatment only after identifying whether residual impairment is medication-related, comorbid, or contextual. [1][2] |
| Cardiovascular parameters | Resting heart rate and blood pressure. [5] | Reevaluate the medication risk-benefit balance and monitoring plan when clinically meaningful elevation or cardiovascular concerns emerge. [5] |
| Appetite and sleep | Reduced appetite and sleep disturbance relative to pretreatment baseline. [18] | Modify medication strategy if adverse effects compromise functioning or tolerability. [3][18] |
| Mood and tics | Mood lability and tic worsening. [18] | Reassess diagnosis, comorbidity, and medication tolerability; consider a different therapeutic pathway. [3][18] |
| Pregnancy and postpartum | Severity of untreated ADHD, current exposure, and alternatives. [20] | Use individualized counseling; avoid assuming equivalent evidence across stimulants and second-line nonstimulants. [20] |

## Common questions

### Are neuropsychological tests required to diagnose adult ADHD?

No. Adult ADHD remains a clinical diagnosis based on DSM criteria, developmental history, cross-setting impairment, and exclusion of better explanations. Questionnaires such as the ASRS are screening tools; neuropsychological measures may characterize cognitive function but do not independently establish the diagnosis. [10][23]

### When should a clinician switch from a stimulant to a nonstimulant?

Switch or choose a nonstimulant when stimulant benefit is inadequate, adverse effects are unacceptable, misuse risk is material, or cardiovascular concerns make stimulant treatment clinically unsuitable. Atomoxetine, guanfacine, and clonidine are established nonstimulant options but have lower average efficacy than stimulants. [3][4][5]

## References
1. Development of a human analogue ADHD diagnostic system for family dogs | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-09988-8
2. Attention-deficit/hyperactivity disorder | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/nrdp201520
3. External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial | Nature Medicine — www.nature.com — https://www.nature.com/articles/s41591-025-04075-x
4. Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults | Neuropsychopharmacology — www.nature.com — https://www.nature.com/articles/npp2015124
5. Cardiovascular Effects of ADHD Therapies: 
JACC Review Topic of the Week — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2020.05.081
6. Long-Term Cardiovascular Risk Associated With Treatment ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2024.03.375
7. Clinical management recommendations for adults with ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2950285325000626
8. The changing prevalence of ADHD? A systematic review — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0165032725008638
9. Attention deficit hyperactivity disorder — www.sciencedirect.com — https://www.sciencedirect.com/science/chapter/handbook/pii/B978044464148900003X
10. The role of neuropsychological assessment in adults with attention deficit/hyperactivity disorders — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0035378721000424
11. Attention-deficit/hyperactivity disorder and cardiometabolic ... — academic.oup.com — https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwaf151/8111539
12. WHO Expert Committee on Selection and Use of Essential ... — cdn.who.int — https://cdn.who.int/media/docs/default-source/2025-eml-expert-committee/comments/a.19_comments_eunethydis.pdf?sfvrsn=d1ad88fa_1
13. Updated ADHD guideline addresses evaluation, diagnosis ... — publications.aap.org — https://publications.aap.org/aapnews/news/14578/Updated-ADHD-guideline-addresses-evaluation
14. Treatment of the School-Aged Child With Attention-Deficit ... — publications.aap.org — https://publications.aap.org/pediatrics/article/108/4/1033/66997/Clinical-Practice-Guideline-Treatment-of-the
15. Clinical Care of ADHD in Children — www.cdc.gov — https://www.cdc.gov/adhd/hcp/clinical-care/index.html
16. Methylphenidate — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/31/NCT07742631/Prot_SAP_ICF_000.pdf
17. تجویز متیل‌‌فنیدیت در مدیریت اختلال نقص توجه و ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012069.pub2/references/fa
18. Attention-Deficit/Hyperactivity Disorder and Herbal Medicine — applications.emro.who.int — https://applications.emro.who.int/imemrf/J_Med_Plants/J_Med_Plants_2018_17_65_1_6.pdf
19. Metilfenidato para el trastorno de déficit de atención e ... — www.cochranelibrary.com — https://www.cochranelibrary.com/es/cdsr/doi/10.1002/14651858.CD012069.pub2/references/es
20. Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period — www.ajog.org — https://www.ajog.org/article/S0002-9378(24)00376-4/pdf
21. Association of Attention-Deficit Hyperactivity Disorder ... - IOVS — iovs.arvojournals.org — https://iovs.arvojournals.org/article.aspx?articleid=
22. Clinical response to a single-dose methylphenidate challenge is indicative of treatment response at two months in adults with ADHD | Translational Psychiatry — www.nature.com — https://www.nature.com/articles/s41398-025-03557-3
23. A Practical Guide for Diagnosing Adult Attention Deficit Hyperactivity Disorder — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1555415513005187
24. Adult ADHD - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/psychology/adult-adhd

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.